Vir Biotechnology Inc

9 de out. de 2026, 20:02 UTC

Vir Biotechnology receives FDA Fast Track designation for VIR-5500, a PSMA-targeted treatment for metastatic castration-resistant prostate cancer.

8 de out. de 2026, 21:01 UTC

Vir Biotechnology receives FDA Fast Track designation for its investigational treatment VIR-5500 for late-line metastatic castration-resistant prostate cancer.

7 de out. de 2026, 20:07 UTC

Vir Biotechnology's shares fell following the announcement of David Liu as Chief Medical Officer, despite HC Wainwright reaffirming a Buy rating with a $22 price target.

6 de out. de 2026, 20:40 UTC

Vir Biotechnology Inc has advanced in after-market trading, rebounding from earlier lows and achieving its highest cumulative return since Tuesday's close.

5 de out. de 2026, 20:01 UTC

Vir Biotechnology Inc is trading sharply higher, reaching a cumulative return of nearly 6%, near the upper end of its one-month trading range.

2 de out. de 2026, 20:07 UTC

Vir Biotechnology Inc shares fell sharply, continuing a decline from Thursday's close, despite rebounding earlier in the session.

1 de out. de 2026, 20:13 UTC

Vir Biotechnology Inc is advancing in after-market trading, holding steady above its 20-day moving average with a cumulative return since Thursday's close.

30 de set. de 2026, 22:56 UTC

Vir Biotechnology Inc traded modestly lower in after-market hours, continuing a downward trend since Wednesday's close, despite remaining above its 20-day moving average.

29 de set. de 2026, 20:02 UTC

Vir Biotechnology is advancing after partnering with Astellas, securing $335 million to enhance its PRO-XTEN platform and support its Phase 3 hepatitis delta program.

25 de set. de 2026, 19:55 UTC

Vir Biotechnology Inc shares fell, continuing a decline over the past three sessions, and remain below Thursday's close and the 20-day moving average.

24 de set. de 2026, 20:07 UTC

Vir Biotechnology Inc's shares are declining, continuing a downward trend since Wednesday, amid notable selling pressure and unfavorable broader market conditions.

23 de set. de 2026, 20:31 UTC

Vir Biotechnology Inc experienced a notable decline in after-market trading, reaching a low and positioned around the middle of its one-month trading range.

22 de set. de 2026, 23:31 UTC

Vir Biotechnology Inc has seen a significant decline during after-market trading, with volatility indicating a sharp downturn since Tuesday's close.

21 de set. de 2026, 20:31 UTC

Vir Biotechnology Inc has advanced in after-market trading, reaching its highest cumulative return since Monday's close and positioned above its 20-day moving average.

18 de set. de 2026, 19:55 UTC

Vir Biotechnology Inc shares fell sharply, reaching their lowest point around midday and remaining notably below the 20-day moving average.

17 de set. de 2026, 20:07 UTC

Vir Biotechnology is higher amid a biotech sector rally, supported by the SPDR S&P Biotech ETF's rise following Moderna's positive cancer vaccine results.

16 de set. de 2026, 23:06 UTC

Vir Biotechnology Inc is trading modestly higher during after-market hours, continuing a routine pattern with limited fluctuations since Wednesday's close.

15 de set. de 2026, 23:41 UTC

Vir Biotechnology Inc shares are lower in after-market hours, following a broader market decline linked to a drop in the New York Empire State Manufacturing Index.

14 de set. de 2026, 20:13 UTC

Vir Biotechnology Inc shares are higher in after-market hours, continuing a trend of three consecutive sessions in the same direction. No specific news was identified.

11 de set. de 2026, 20:08 UTC

Vir Biotechnology Inc shares are higher during Friday's session, reflecting broader market trends. The stock experienced volatility, reaching a high shortly after the open.

9 de set. de 2026, 20:07 UTC

Vir Biotechnology Inc shares are lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 de set. de 2026, 19:46 UTC

Vir Biotechnology Inc shares are lower during Thursday's session, reversing early gains amid significant volatility. No specific news was identified to explain the decline.

2 de set. de 2026, 23:16 UTC

Vir Biotechnology shares are lower in after-market trading, despite strong one-month performance. The stock remains above its 20-day moving average.

1 de set. de 2026, 22:06 UTC

Vir Biotechnology Inc. has a market cap of $1.6 billion and cash of $1 billion. Shares are higher in after-market trading following recent strong performance.

28 de ago. de 2026, 20:08 UTC

Vir Biotechnology Inc shares are lower today, continuing a decline since Thursday amid rising U.S. Treasury yields and broader market pressures.

27 de ago. de 2026, 20:08 UTC

Vir Biotechnology Inc shares are higher, reflecting a steady upward trend since Wednesday. Broader market conditions may be contributing to this positive movement.

26 de ago. de 2026, 20:08 UTC

Vir Biotechnology Inc is higher in Wednesday's session, continuing its upward trend since Tuesday's close, despite earlier fluctuations in price.

25 de ago. de 2026, 20:09 UTC

Vir Biotechnology is gaining as social media discussions highlight its $1 billion cash position and potential catalysts, despite earlier session pullbacks.

24 de ago. de 2026, 21:01 UTC

Vir Biotechnology Inc. shares are trading higher in after-market hours, continuing a recent upward trend amid a rebound in the bond market and lower Treasury yields.

21 de ago. de 2026, 20:02 UTC

Vir Biotechnology Inc. shows upward momentum, reflecting significant gains since Thursday's close, amid positive trends in the healthcare sector and broader biotechnology market.